Armando Anido - Sep 12, 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Chairman & Chief Exec. Officer, Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Sep 12, 2023
Transactions value $
-$23,637
Form type
4
Date filed
9/14/2023, 04:13 PM
Previous filing
Jun 20, 2023
Next filing
Oct 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +64.7K +7.28% 955K Sep 12, 2023 Direct F1
transaction ZYNE Common Stock Sale -$23.6K -17.8K -1.87% $1.33 937K Sep 13, 2023 Direct F2
holding ZYNE Common Stock 26.6K Sep 12, 2023 See footnote F3
holding ZYNE Common Stock 13.3K Sep 12, 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 64,747 performance-based restricted stock awards granted in a prior year.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.